Association of individual chromosomal aberrations with progression to secondary myelofibrosis/accelerated phase
| Aberration type . | sMF/AP (n = 58) . | Chronic MPN (n = 321) . | P . | P* . | |
|---|---|---|---|---|---|
| gain | 1q | 7 (12.07%) | 2 (0.62%) | 3.98 × 10−5 | .0010 |
| UPD | 9p | 38 (65.52%) | 120 (37.38%) | 8.15 × 10−5 | .0020 |
| deletion | 12q | 3 (5.17%) | 1 (0.31%) | .0122 | .3053 |
| UPD | 14q | 4 (6.90%) | 4 (1.25%) | .0216 | .5393 |
| UPD | 11q | 2 (3.45%) | 0 (0.00%) | .0231 | .5770 |
| deletion | 20q | 5 (8.62%) | 7 (2.18%) | .0239 | .5963 |
| deletion | 7q | 3 (5.17%) | 2 (0.62%) | .0272 | .6798 |
| deletion | 4q | 4 (6.90%) | 5 (1.56%) | .0344 | .8605 |
| deletion | 12p | 2 (3.45%) | 2 (0.62%) | .1125 | 1 |
| deletion | 7p | 1 (1.72%) | 0 (0.00%) | .1530 | 1 |
| trisomy | 21 | 1 (1.72%) | 0 (0.00%) | .1530 | 1 |
| UPD | 1p | 2 (3.45%) | 4 (1.25%) | .2299 | 1 |
| UPD | 22q | 1 (1.72%) | 1 (0.31%) | .2830 | 1 |
| trisomy | 9 | 2 (3.45%) | 5 (1.56%) | .2916 | 1 |
| UPD | 7q | 1 (1.72%) | 2 (0.62%) | .3933 | 1 |
| deletion | 13q | 3 (5.17%) | 9 (2.80%) | .4051 | 1 |
| deletion | 3p | 1 (1.72%) | 3 (0.93%) | .4869 | 1 |
| gain | 9p | 1 (1.72%) | 4 (1.25%) | .5662 | 1 |
| gain | 3q | 0 (0.00%) | 1 (0.31%) | 1 | 1 |
| deletion | 5q | 0 (0.00%) | 1 (0.31%) | 1 | 1 |
| deletion | 6p | 0 (0.00%) | 1 (0.31%) | 1 | 1 |
| trisomy | 8 | 1 (1.72%) | 5 (1.56%) | 1 | 1 |
| deletion | 11q | 0 (0.00%) | 3 (0.93%) | 1 | 1 |
| deletion | 18p | 0 (0.00%) | 4 (1.25%) | 1 | 1 |
| UPD | 19q | 0 (0.00%) | 0 (0.00%) | 1 | 1 |
| Aberration type . | sMF/AP (n = 58) . | Chronic MPN (n = 321) . | P . | P* . | |
|---|---|---|---|---|---|
| gain | 1q | 7 (12.07%) | 2 (0.62%) | 3.98 × 10−5 | .0010 |
| UPD | 9p | 38 (65.52%) | 120 (37.38%) | 8.15 × 10−5 | .0020 |
| deletion | 12q | 3 (5.17%) | 1 (0.31%) | .0122 | .3053 |
| UPD | 14q | 4 (6.90%) | 4 (1.25%) | .0216 | .5393 |
| UPD | 11q | 2 (3.45%) | 0 (0.00%) | .0231 | .5770 |
| deletion | 20q | 5 (8.62%) | 7 (2.18%) | .0239 | .5963 |
| deletion | 7q | 3 (5.17%) | 2 (0.62%) | .0272 | .6798 |
| deletion | 4q | 4 (6.90%) | 5 (1.56%) | .0344 | .8605 |
| deletion | 12p | 2 (3.45%) | 2 (0.62%) | .1125 | 1 |
| deletion | 7p | 1 (1.72%) | 0 (0.00%) | .1530 | 1 |
| trisomy | 21 | 1 (1.72%) | 0 (0.00%) | .1530 | 1 |
| UPD | 1p | 2 (3.45%) | 4 (1.25%) | .2299 | 1 |
| UPD | 22q | 1 (1.72%) | 1 (0.31%) | .2830 | 1 |
| trisomy | 9 | 2 (3.45%) | 5 (1.56%) | .2916 | 1 |
| UPD | 7q | 1 (1.72%) | 2 (0.62%) | .3933 | 1 |
| deletion | 13q | 3 (5.17%) | 9 (2.80%) | .4051 | 1 |
| deletion | 3p | 1 (1.72%) | 3 (0.93%) | .4869 | 1 |
| gain | 9p | 1 (1.72%) | 4 (1.25%) | .5662 | 1 |
| gain | 3q | 0 (0.00%) | 1 (0.31%) | 1 | 1 |
| deletion | 5q | 0 (0.00%) | 1 (0.31%) | 1 | 1 |
| deletion | 6p | 0 (0.00%) | 1 (0.31%) | 1 | 1 |
| trisomy | 8 | 1 (1.72%) | 5 (1.56%) | 1 | 1 |
| deletion | 11q | 0 (0.00%) | 3 (0.93%) | 1 | 1 |
| deletion | 18p | 0 (0.00%) | 4 (1.25%) | 1 | 1 |
| UPD | 19q | 0 (0.00%) | 0 (0.00%) | 1 | 1 |
After Bonferroni correction for multiple testing; significant associations are bold.